Cargando…

Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region

Previous studies investigated the efficacy and the safety of bendamustine (B) vs. chlorambucil (Chl) associated with rituximab (R) in fludarabine-ineligible patients with treated and untreated chronic lymphocytic leukemia (CLL). We conducted a retrospective multicenter study in the Lazio region to f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Autore, Francesco, Innocenti, Idanna, Corrente, Francesco, Del Principe, Maria Ilaria, Rosati, Serena, Falcucci, Paolo, Fresa, Alberto, Conte, Esmeralda, Limongiello, Maria Assunta, Renzi, Daniela, De Padua, Laura, Andriani, Alessandro, Pisani, Francesco, Cimino, Giuseppe, Tafuri, Agostino, Montanaro, Marco, Mauro, Francesca Romana, Del Poeta, Giovanni, Laurenti, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298101/ https://www.ncbi.nlm.nih.gov/pubmed/32587827 http://dx.doi.org/10.3389/fonc.2020.00848

Ejemplares similares

Chlorambucil plus Rituximab as Front-Line Therapy in Elderly/Unfit Patients Affected by B-Cell Chronic Lymphocytic Leukemia: Results of a Single-Centre Experience
por: Laurenti, Luca, et al.
Publicado: (2013)

Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study
por: Michallet, Anne-Sophie, et al.
Publicado: (2018)

Evidence of bendamustine plus rituximab for old and frail patients with aggressive B-cell lymphoma
por: Schalk, Enrico, et al.
Publicado: (2023)

Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL
por: Tisi, Maria Chiara, et al.
Publicado: (2023)

Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
por: Murayama, Kayoko, et al.
Publicado: (2022)

Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases
por: Visentin, Andrea, et al.
Publicado: (2017)

Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
por: Bega, Giulia, et al.
Publicado: (2021)

Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)
por: Stilgenbauer, Stephan, et al.
Publicado: (2020)

An unusual case of primary hepatic lymphoma with dramatic but unsustained response to bendamustine plus rituximab and literature review
por: Liao, Sih-Han, et al.
Publicado: (2017)

Severe Liver Damage and Nonallergic Bronchitis with Eosinophilia in a Patient with Follicular Lymphoma Treated with Bendamustine plus Rituximab
por: Jo, Tatsuro, et al.
Publicado: (2014)

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data
por: Sehn, Laurie H., et al.
Publicado: (2022)

Prognostic role of translocator protein and oxidative stress markers in chronic lymphocytic leukemia patients treated with bendamustine plus rituximab
por: DE ROSA, ANIELLO, et al.
Publicado: (2015)

Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab
por: Rai, Shinya, et al.
Publicado: (2018)

Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202
por: Ruppert, Amy S., et al.
Publicado: (2021)

Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia: A Comprehensive Review
por: Autore, Francesco, et al.
Publicado: (2021)

Bendamustine/dexamethasone/rituximab: Cytomegalovirus reactivation : case report
Publicado: (2021)

Bendamustine/rituximab: COVID-19 pneumonia: case report
Publicado: (2021)

Bendamustine/rituximab: Neutropenia, fever and inflammation: case report
Publicado: (2022)

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
por: Leonard, John P., et al.
Publicado: (2019)

Case Report: High Doses of Intravenous Immunoglobulins as a Successful Treatment for Late Onset Immune Agranulocytosis After Rituximab Plus Bendamustine
por: Diez-Feijóo, Ramon, et al.
Publicado: (2022)

Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study
por: Fresa, Alberto, et al.
Publicado: (2022)

Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone
por: Cheson, Bruce D., et al.
Publicado: (2016)

Treatment Options for Elderly/Unfit Patients with Chronic Lymphocytic Leukemia in the Era of Targeted Drugs: A Comprehensive Review
por: Fresa, Alberto, et al.
Publicado: (2021)

Successful Treatment of Factor X Deficiency in a Patient with Lymphoplasmacytic Lymphoma with Bendamustine Plus Rituximab Regimen: A Case Report and Literature Review
por: Rungjirajittranon, Tarinee, et al.
Publicado: (2021)

Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study
por: Buske, Christian, et al.
Publicado: (2022)

Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi
por: Margiotta-Casaluci, Gloria, et al.
Publicado: (2023)

Perforating Folliculitis Secondary to Bendamustine-Rituximab Chemotherapy: A Case Report
por: Monteiro, Rowan, et al.
Publicado: (2017)

Painful, plantar nodules in cutaneous macroglobulinosis: Successful treatment with rituximab and bendamustine
por: D'Acunto, Carmine, et al.
Publicado: (2020)

Large B - Cell Lymphoma of the Leg – Unfavourable Course with Rituximab/Bendamustin
por: Wollina, Uwe, et al.
Publicado: (2019)

Long-term follow-up after rituximab plus bendamustine in a patient with relapsed or refractory hairy cell leukemia variant: A case report
por: Imoto, Naoto, et al.
Publicado: (2021)

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial
por: Zinzani, Pier Luigi, et al.
Publicado: (2012)

Role of microRNAs in Chronic Lymphocytic Leukemia
por: Autore, Francesco, et al.
Publicado: (2023)

Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost‐effectiveness analysis
por: Zhang, Peng‐Fei, et al.
Publicado: (2020)

A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE
por: van Dam, Laura S, et al.
Publicado: (2020)

A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy
por: Kamegai, Kohei, et al.
Publicado: (2022)

An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma
por: Alderuccio, Juan Pablo, et al.
Publicado: (2022)

A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL
por: Jain, Nitin, et al.
Publicado: (2016)

Measurable residual disease in chronic lymphocytic leukemia
por: Benintende, Giulia, et al.
Publicado: (2023)

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
por: Morschhauser, Franck, et al.
Publicado: (2022)

Chronic Lymphocytic Leukaemia: Census of Patients Treated in Italian Haematology Units
por: Salvi, Gianfranco, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_j0t5a264m3mj8ldl1u3sk875o7